Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína β-amiloide
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
La enfermedad de Alzheimer (EA) es el principal trastorno neurodegenerativo que provoca una discapacidad intelectual total en los pacientes que la presentan. La elevada prevalencia a nivel mundial, así como la elevada carga socioeconómica que conlleva la EA para la sociedad en general, hace que sea considerada un importante problema de salud pública en este siglo xxi. En este trabajo se revisan los tratamientos actuales y en fase de desarrollo que actúan principalmente sobre la proteína β-amiloide. La hipótesis amiloidogénica propone que el péptido β-amiloide tiene un papel clave en esta enfermedad. Se han desarrollado varias estrategias farmacológicas diferentes con el objetivo de inhibir la formación de los péptidos β-amiloides, como son los inhibidores de β-secretasa y γ-secretasa. Además, se han desarrollado los tratamientos antiamiloide, que incluyen inmunoterapias pasivas y activas enfocadas a inhibir la agregación del péptido β-amiloide. Los avances en la identificación de las bases moleculares de la EA pueden servir como modelo para comprender las causas de esta enfermedad neurodegenerativa. Sin embargo, los ensayos clínicos más recientes en 2 ensayos de fase iii con solanezumab, un anticuerpo monoclonal humanizado que promueve el aclaramiento del β-amiloide en el cerebro, indican que este anticuerpo no muestra eficacia en pacientes con EA leve, sugiriendo que hay que replantearse esta hipótesis amiloidogénica de la EA. Alzheimer disease (AD) is a major neurodegenerative disorder which eventually results in total intellectual disability. The high global prevalence and the socioeconomic burden associated with the disease pose major challenges for public health in the 21st century. In this review we focus on both existing treatments and the therapies being developed, which principally target the β-amyloid protein. The amyloidogenic hypothesis proposes that β-amyloid plays a key role in AD. Several pharmacological approaches aim to reduce the formation of β-amyloid peptides by inhibiting the β-secretase and γ-secretase enzymes. In addition, both passive and active immunotherapies have been developed for the purpose of inhibiting β-amyloid peptide aggregation. Progress in identifying the molecular basis of AD may provide better models for understanding the causes of this neurodegenerative disease. The lack of efficacy of solanezumab (a humanised monoclonal antibody that promotes β-amyloid clearance in the brain), demonstrated by 2 recent Phase III clinical trials in patients with mild AD, suggests that the amyloidogenic hypothesis needs to be revised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“…fragmentos (s)APP (cid:2) y A (cid:2) 40/42, que quedan en el espacio extracelular, y un fragmento C-terminal de 99 aminoácidos (C99), que puede ser transportado hacia el interior de la célula y translocado al núcleo, donde podría inducir la expresión de genes 6,7 muerte neuronal por apoptosis .”
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“Bapineuzumab es un anticuerpo monoclonal humanizado contra el extremo N-terminal de la proteína (cid:2) A (A (cid:2) 1-5), mientras que solane-zumab es un anticuerpo monoclonal humanizado dise˜nado para unirse la porción central de la proteína (cid:2) A (A (cid:2) 12-28) 59,60 .”
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 3×
“…la disminución de la producción de (cid:2) A42 y la fosforilación de la proteína tau, ade-más de la prevención de la agregación o mal plegamiento de estas proteínas, neutralizar o eliminar las formas agregadas o mal plegadas tóxicas de estas proteínas, o una combina-ción de estas modalidades 4-9 .”
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Trafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075 · cited 3×
“…fragmentos (s)APP (cid:2) y A (cid:2) 40/42, que quedan en el espacio extracelular, y un fragmento C-terminal de 99 aminoácidos (C99), que puede ser transportado hacia el interior de la célula y translocado al núcleo, donde podría inducir la expresión de genes 6,7 muerte neuronal por apoptosis .”
Neurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
Mucke, L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006338 · Cited by 1,000
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448
Research works printed but not linked: 50
- Thies, 2013, Alzheimer's Association. 2013 Alzheimer's disease facts and figures, Alzheimers Dement., 9, 208, 10.1016/j.jalz.2013.02.003 · DOI · Paper page
- Chiang, 2014, Emerging therapeutics for Alzheimer's disease, Annu Rev Pharmacol Toxicol., 54, 381, 10.1146/annurev-pharmtox-011613-135932 · DOI · Paper page
- Francis, 2005, A preclinical view of cholinesterase inhibitors in neuroprotection: Do they provide more than symptomatic benefits in Alzheimer's disease, Trends Pharmacol Sci., 26, 104, 10.1016/j.tips.2004.12.010 · DOI
- Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics, Science., 297, 353, 10.1126/science.1072994 · DOI · Paper page
- Castello, 2013, Rational heterodoxy: Cholesterol reformation of the amyloid doctrine, Ageing Res Rev, 12, 282, 10.1016/j.arr.2012.06.007 · DOI · Paper page
- Castello, 2014, On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis, Ageing Res Rev, 13, 10, 10.1016/j.arr.2013.10.001 · DOI
- Ferreira, 2014, Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease, Alzheimers Dement., 10, S76, 10.1016/j.jalz.2013.12.010 · DOI · Paper page
- De Felice, 2014, Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease, Diabetes., 63, 2262, 10.2337/db13-1954 · DOI · Paper page
- De Felice, 2013, Alzheimer's disease and insulin resistance: Translating basic science into clinical applications, J Clin Invest., 123, 531, 10.1172/JCI64595 · DOI · Paper page
- Vassar, 2011, The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease, Alzheimer's Res Ther., 3, 20, 10.1186/alzrt82 · DOI · Paper page
- Menting, 2014, β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease, Front Aging Neurosci., 6, 165, 10.3389/fnagi.2014.00165 · DOI · Paper page
- Yan, 2014, Targeting the β secretase BACE1 for Alzheimer's disease therapy, Lancet Neurol., 13, 319, 10.1016/S1474-4422(13)70276-X · DOI · Paper page
- Chiang, 2014, Emerging therapeutics for Alzheimer's disease, Annu Rev Pharmacol Toxicol., 54, 381, 10.1146/annurev-pharmtox-011613-135932 · DOI · Paper page
- Imbimbo, 2011, γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes, Curr Top Med Chem., 11, 1555, 10.2174/156802611795860942 · DOI · Paper page
- Wolfe, 2012, γ-secretase as a target for Alzheimer's disease, Adv Pharmacol., 64, 127, 10.1016/B978-0-12-394816-8.00004-0 · DOI
- Coric, 2012, Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease, Arch Neurol., 69, 1430, 10.1001/archneurol.2012.2194 · DOI · Paper page
- Dockens, 2012, A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects, Clin Pharmacokinet., 51, 681, 10.1007/s40262-012-0005-x · DOI
- Tong, 2012, Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men, Clin Drug Investig., 32, 761, 10.1007/s40261-012-0006-4 · DOI
- Jaturapatporn, 2012, Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease, Cochrane Database Syst Rev., 2, CD006378
- Ross, 2013, CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: A 12-week, double-blind, placebo-controlled study, Curr Alzheimer Res., 10, 742, 10.2174/13892037113149990144 · DOI · Paper page
- Imbimbo, 2013, Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects, Alzheimer Dis Assoc Disord., 27, 278, 10.1097/WAD.0b013e3182622ace · DOI
- Ronsisvalle, 2014, CHF5074 protects SH-SY5Y human neuronal-like cells from amyloidbeta 25-35 and tumor necrosis factor related apoptosis inducing ligand toxicity in vitro, Curr Alzheimer Res., 11, 714, 10.2174/1567205011666140618104430 · DOI
- Lee, 2014, Ice plant (Mesembryanthemum crystallinum) improves hyperglycaemia and memory impairments in a Wistar rat model of streptozotocin-induced diabetes, J Sci Food Agric., 94, 2266, 10.1002/jsfa.6552 · DOI
- Pitt, 2013, Protection against the synaptic targeting and toxicity of Alzheimer's-associated Aβ oligomers by insulin mimetic chiro-inositols, FASEB J., 27, 199, 10.1096/fj.12-211896 · DOI · Paper page
- Obregon, 2006, ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein, J Biol Chem., 281, 16419, 10.1074/jbc.M600617200 · DOI · Paper page
- Etcheberrigaray, 2004, Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice, Proc Natl Acad Sci U S A., 101, 11141, 10.1073/pnas.0403921101 · DOI · Paper page
- Holthoewer, 2012, Acitretin an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein, Neurodegener Dis., 10, 224, 10.1159/000334300 · DOI
- Tippmann, 2009, Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin, FASEB J., 23, 1643, 10.1096/fj.08-121392 · DOI · Paper page
- Endres, 2014, Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin, Neurology., 83, 1930, 10.1212/WNL.0000000000001017 · DOI · Paper page
- Gauthier, 2009, Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: Exploratory analyses of the MRI sub-group of the Alphase study, J Nutr Health Aging., 13, 550, 10.1007/s12603-009-0106-x · DOI · Paper page
- Bilikiewicz, 2004, Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease, J Alzheimers Dis., 6, 17, 10.3233/JAD-2004-6103 · DOI · Paper page
- Aytan, 2013, Combination therapy in a transgenic model of Alzheimer's disease, Exp Neurol., 250, 228, 10.1016/j.expneurol.2013.10.001 · DOI · Paper page
- Matlack, 2014, Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity, Proc Natl Acad Sci U S A., 111, 4013, 10.1073/pnas.1402228111 · DOI · Paper page
- Nalivaeva, 2008, Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease, Curr Alzheimer Res., 5, 212, 10.2174/156720508783954785 · DOI · Paper page
- Higuchi, 2005, Understanding molecular mechanisms of proteolysis in Alzheimer's disease: Progress toward therapeutic interventions, Biochim Biophys Acta., 1751, 60, 10.1016/j.bbapap.2005.02.013 · DOI
- Deane, 2012, Is RAGE still a therapeutic target for Alzheimer's disease?, Future Med Chem., 4, 915, 10.4155/fmc.12.51 · DOI · Paper page
- Deane, 2008, The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease, Curr Pharm Des., 14, 1601, 10.2174/138161208784705487 · DOI · Paper page
- Bates, 2009, Clearance mechanisms of Alzheimer's amyloid-beta peptide: Implications for therapeutic design and diagnostic tests, Mol Psychiatry., 14, 469, 10.1038/mp.2008.96 · DOI · Paper page
- Galasko, 2014, Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease, Neurology., 82, 1536, 10.1212/WNL.0000000000000364 · DOI · Paper page
- Wiessner, 2011, The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects, J Neurosci., 31, 9323, 10.1523/JNEUROSCI.0293-11.2011 · DOI · Paper page
- Muhs, 2007, Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice, Proc Natl Acad Sci U S A, 104, 9810, 10.1073/pnas.0703137104 · DOI · Paper page
- Liu, 2013, MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice, J Neurosci., 33, 7027, 10.1523/JNEUROSCI.5924-12.2013 · DOI · Paper page
- Panza, 2014, Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: The point of no return, Expert Opin Biol Ther, 14, 1465, 10.1517/14712598.2014.935332 · DOI · Paper page
- Panza, 2014, Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: The way forward, Expert Rev Clin Immunol., 10, 405, 10.1586/1744666X.2014.883921 · DOI · Paper page
- Novakovic, 2013, Profile of gantenerumab and its potential in the treatment of Alzheimer's disease, Drug Des Devel Ther., 7, 1359
- Jacobsen, 2014, Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APP London mice, J Neurosci., 34, 11621, 10.1523/JNEUROSCI.1405-14.2014 · DOI · Paper page
- Jindal, 2014, Alzheimer disease immunotherapeutics: Then and now, Hum Vaccin Immunother., 10, 2741, 10.4161/21645515.2014.970959 · DOI · Paper page
- Dodel, 2013, Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: A phase 2, randomised, double-blind, placebo-controlled, dose-finding trial, Lancet Neurol., 12, 233, 10.1016/S1474-4422(13)70014-0 · DOI · Paper page
- Relkin, 2009, 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease, Neurobiol Aging., 30, 1728, 10.1016/j.neurobiolaging.2007.12.021 · DOI · Paper page
- Szabo, 2010, Measurement of anti-beta amyloid antibodies in human blood, J Neuroimmunol., 227, 167, 10.1016/j.jneuroim.2010.06.010 · DOI
Cited by
Antioxidant and Oxidative Stress: A Mutual Interplay in Age-Related Diseases
Tan, B. L., Norhaizan, M. E., Liew, W.-P.-P., & Sulaiman Rahman, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01162 · Cited by 1,149
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239
Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development
Mueed, Z., Tandon, P., Maurya, S. K., Deval, R., Kamal, M. A., & Poddar, N. K. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01017 · Cited by 111
Aducanumab—Hope or Disappointment for Alzheimer’s Disease
Wojtunik-Kulesza, K., Rudkowska, M., & Orzeł-Sajdłowska, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054367 · Cited by 73
Metadata
- Authors
- Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedrós, I., Marin, M., Olloquequi, J., & Camins, A.
- Venue
- Neurología
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 33
- Issue
- 1
- Pages
- 47-58
- ISSN
- 0213-4853 (ISSN-L)
- OpenAlex
- W2608752954
- Cited by
- 97
- References
- 18
- FWCI
- 1.29
- Type
- journal article
- Language
- es
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína β-amiloide. https://app.cochat.ai/papers/10.1016/j.nrl.2015.03.012
- The paper
- Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedrós, I., Marin, M., Olloquequi, J., & Camins, A. (2018). Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína β-amiloide. Neurología. https://doi.org/10.1016/j.nrl.2015.03.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.